{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:11:38Z","timestamp":1793232698740,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP223fa627004"],"award-info":[{"award-number":["JP223fa627004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015060","name":"Nagasaki University","doi-asserted-by":"publisher","award":["672009"],"award-info":[{"award-number":["672009"]}],"id":[{"id":"10.13039\/100015060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023693","name":"Vaccine Impact Modelling Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill &amp; Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-034281"],"award-info":[{"award-number":["INV-034281"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jvacx.2024.100568","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T19:35:27Z","timestamp":1727811327000},"page":"100568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Typhoid conjugate vaccine implementation in India: A review of supportive evidence"],"prefix":"10.1016","volume":"21","author":[{"given":"Vijayalaxmi V.","family":"Mogasale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Hasan Farooqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Chantler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittal","family":"Mogasale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhim","family":"Gopal Dhoubhadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"John Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.vaccine.2012.10.103","article-title":"Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review","volume":"31","author":"Ozawa","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1377\/hlthaff.2015.1086","article-title":"Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011\u201320","volume":"35","author":"Ozawa","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"34","key":"10.1016\/j.jvacx.2024.100568_b0015","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jvacx.2024.100568_b0020","unstructured":"World Health Organization 2021. WHO recommendations for routine immunization, Table 1. Available at: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/policies\/who-recommendations-for-routine-immunization---summary-tables. Accessed February 26, 2023."},{"key":"10.1016\/j.jvacx.2024.100568_b0025","unstructured":"World Health Organization, 2022. Pneumococcal vaccines. Available at: https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/vaccine-standardization\/pneumococcal-disease. Accessed April 1, 2023."},{"key":"10.1016\/j.jvacx.2024.100568_b0030","unstructured":"World Health Organization 2022. Global immunization coverage 2021. April Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage. Accessed April 1, 2023."},{"issue":"Suppl 2","key":"10.1016\/j.jvacx.2024.100568_b0035","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1093\/cid\/ciy1118","article-title":"Accelerating Typhoid Conjugate Vaccine Introduction: What Can Be Learned From Prior New Vaccine Introduction Initiatives?","volume":"68","author":"Jamka","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1377\/hlthaff.2015.1079","article-title":"Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs","volume":"35","author":"Kallenberg","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100568_b0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"Global Burden of Disease 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"Stanaway","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jvacx.2024.100568_b0050","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1093\/cid\/ciy1111","article-title":"Antibiotic Resistance and Typhoid","volume":"68","author":"Dyson","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100568_b0055","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100568_b0060","doi-asserted-by":"crossref","first-page":"e0004616","DOI":"10.1371\/journal.pntd.0004616","article-title":"The Burden of Typhoid and Paratyphoid in India: Systematic Review and Meta-analysis","volume":"10","author":"John","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"16","key":"10.1016\/j.jvacx.2024.100568_b0065","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2209449","article-title":"Burden of Typhoid and Paratyphoid Fever in India","volume":"388","author":"John","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100568_b0070","first-page":"491","article-title":"A brief history of vaccines & vaccination in India","volume":"139","author":"Lahariya","year":"2014","journal-title":"Indian J Med Res"},{"issue":"Suppl 3","key":"10.1016\/j.jvacx.2024.100568_b0075","doi-asserted-by":"crossref","first-page":"C55","DOI":"10.1016\/j.vaccine.2015.04.028","article-title":"Typhoid fever vaccination strategies","volume":"33","author":"Date","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100568_b0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa0807521","article-title":"A cluster-randomized effectiveness trial of Vi typhoid vaccine in India","volume":"361","author":"Sur","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100568_b0085","unstructured":"Coalitionagainsttyphoid.org. Typhoid Vaccines 2022. Available at: https:\/\/www.coalitionagainsttyphoid.org\/the-issues\/typhoid-vaccines\/. Accessed January 8, 2023."},{"issue":"Suppl 2","key":"10.1016\/j.jvacx.2024.100568_b0090","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1093\/cid\/ciaa597","article-title":"Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018","volume":"71","author":"Date","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0095","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018 - Recommendations","volume":"37","author":"World Health Organization.","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100568_b0100","unstructured":"Ministry of Health and Family Welfare, Immunization Division 2022. Minutes of the meeting of 17th National Technical Advisory Group on Immunization (NTAGI), held on 28th June 2022, under the Chairpersonship of Secretary (Health & Family Welfare) at Nirman Bhawan, New Delhi. Available at: https:\/\/main.mohfw.gov.in\/sites\/default\/files\/17th%20NTAGI%20Meeting%20Minutes%20June%2028%2C%202022.pdf. Accessed January 8,2023."},{"key":"10.1016\/j.jvacx.2024.100568_b0105","doi-asserted-by":"crossref","unstructured":"Wang SA, Hyde TB, Mounier-Jack S, Brenzel L, Favin M, Gordon WS, et al. New vaccine introductions: assessing the impact and the opportunities for immunization and health systems strengthening. Vaccine. 2013;31 Suppl 2(0 2):B122-8.","DOI":"10.1016\/j.vaccine.2012.10.116"},{"key":"10.1016\/j.jvacx.2024.100568_b0110","unstructured":"World Health Organization. Regional Office for Europe. Guidance on an adapted evidence to recommendation process for National Immunization Technical Advisory Groups, 2022. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/356896. Accessed January 8, 2023."},{"key":"10.1016\/j.jvacx.2024.100568_b0115","series-title":"Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring","first-page":"2014","author":"World Health Organization.","year":"2014"},{"key":"10.1016\/j.jvacx.2024.100568_b0120","article-title":"World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring. Geneva: World Health","year":"2014","journal-title":"Organization"},{"key":"10.1016\/j.jvacx.2024.100568_b0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12879-016-1351-3","article-title":"Revisiting typhoid fever surveillance in low and middle income countries: lessons from systematic literature review of population-based longitudinal studies","volume":"16","author":"Mogasale","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"9180","key":"10.1016\/j.jvacx.2024.100568_b0130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0140-6736(98)09001-1","article-title":"Typhoid fever in children aged less than 5 years","volume":"354","author":"Sinha","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100568_b0135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2471\/BLT.06.039818","article-title":"A study of typhoid fever in five Asian countries: disease burden and implications for controls","volume":"86","author":"Ochiai","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"Supple 5","key":"10.1016\/j.jvacx.2024.100568_b0140","doi-asserted-by":"crossref","first-page":"S558","DOI":"10.1093\/infdis\/jiab046","article-title":"Incidence of Enteric Fever in a Pediatric Cohort in North India: Comparison with Estimates from 20 Years Earlier","volume":"224","author":"Sinha","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100568_b0145","doi-asserted-by":"crossref","unstructured":"Cao Y, Karthikeyan AS, Ramanujam K, Raju R, Krishna S, Kumar D, et al. Geographic Pattern of Typhoid Fever in India: A Model-Based Estimate of Cohort and Surveillance Data. J Infect Dis. 2021;224(224 Supple 5):S475-S83.","DOI":"10.1093\/infdis\/jiab187"},{"issue":"Supple 5","key":"10.1016\/j.jvacx.2024.100568_b0150","doi-asserted-by":"crossref","first-page":"S517","DOI":"10.1093\/infdis\/jiab388","article-title":"Case-Fatality Ratio of Enteric Fever: Estimates From Multitiered Surveillance in India","volume":"224","author":"Samuel","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100568_b0155","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22.","DOI":"10.1016\/S0140-6736(20)30925-9"},{"issue":"Suppl 1","key":"10.1016\/j.jvacx.2024.100568_b0160","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/ofid\/ofad041","article-title":"Combination Vaccines: Moving Beyond Typhoid","volume":"10","author":"MacLennan","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100568_b0165","first-page":"304","article-title":"Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy","volume":"22","author":"Bahl","year":"2004","journal-title":"J Health Popul Nutr"},{"issue":"Supple 5","key":"10.1016\/j.jvacx.2024.100568_b0170","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1093\/infdis\/jiab282","article-title":"Cost of Illness Due to Severe Enteric Fever in India","volume":"224","author":"Kumar","year":"2021","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100568_b0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-3156.2010.02711.x","article-title":"Cost of illness due to typhoid fever in five Asian countries","volume":"16","author":"Poulos","year":"2011","journal-title":"Trop Med Int Health"},{"issue":"12 Suppl 2","key":"10.1016\/j.jvacx.2024.100568_b0180","doi-asserted-by":"crossref","first-page":"S788","DOI":"10.1093\/infdis\/jiab443","article-title":"Typhoid Conjugate Vaccine: An Urgent Tool to Combat Typhoid and Tackle Antimicrobial Resistance","volume":"224","author":"Saha","year":"2021","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0185","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/ijmr.IJMR_830_18","article-title":"A systematic review of antimicrobial resistance of typhoidal","volume":"149","author":"Britto","year":"2019","journal-title":"Indian J Med Res"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0190","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1038\/s41467-023-42353-9","article-title":"Assessing the global risk of typhoid outbreaks caused by extensively drug resistant Salmonella Typhi","volume":"14","author":"Walker","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0195","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/ijmr.IJMR_2074_17","article-title":"Developing a hybrid antimicrobial resistance surveillance system in India: Needs & challenges","volume":"149","author":"Kaur","year":"2019","journal-title":"Indian J Med Res"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/ijmr.IJMR_226_18","article-title":"Establishing Antimicrobial Resistance Surveillance & Research Network in India: Journey so far","volume":"149","author":"Walia","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jvacx.2024.100568_b0205","article-title":"ICMR's Antimicrobial Resistance Surveillance system (JAC","volume":"3(1):dlab023","author":"Kaur","year":"2021","journal-title":"Antimicrob Resist"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100568_b0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100568_b0215","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1093\/cid\/ciab059","article-title":"Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018","volume":"73","author":"Longley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100568_b0220","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad132","article-title":"Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India","author":"Hoffman","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100568_b0225","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1016\/S2214-109X(21)00255-2","article-title":"Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study","volume":"9","author":"Yousafzai","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"36","key":"10.1016\/j.jvacx.2024.100568_b0230","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1016\/j.vaccine.2022.06.072","article-title":"Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh","volume":"40","author":"Thobani","year":"2022","journal-title":"Pakistan Vaccine"},{"issue":"40","key":"10.1016\/j.jvacx.2024.100568_b0235","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1016\/j.vaccine.2021.08.051","article-title":"Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study","volume":"39","author":"Batool","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0240","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2214-109X(22)00466-1","article-title":"Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data","volume":"11","author":"Liang","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"31","key":"10.1016\/j.jvacx.2024.100568_b0245","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1016\/j.vaccine.2022.04.093","article-title":"Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: A matched case control study","volume":"40","author":"Lightowler","year":"2022","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100568_b0250","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children","volume":"385","author":"Patel","year":"2021","journal-title":"N Engl J Med"},{"issue":"10301","key":"10.1016\/j.jvacx.2024.100568_b0255","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jvacx.2024.100568_b0260","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N Engl J Med"},{"issue":"10425","key":"10.1016\/j.jvacx.2024.100568_b0265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(23)02031-7","article-title":"Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children","volume":"403","author":"Patel","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2024.100568_b0270","unstructured":"John J. Vellore Typhoid Vaccine Impact Trial (VEVACT)2023 [cited 2023 April 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05500482."},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0275","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s13063-023-07555-y","article-title":"An observer-blinded, cluster randomised trial of a typhoid conjugate vaccine in an urban South Indian cohort","volume":"24","author":"Sahai","year":"2023","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100568_b0280","article-title":"Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics","volume":"9","author":"Haselbeck","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jvacx.2024.100568_b0285","unstructured":"International Vaccine Insititute 2021. Effectiveness of a Typhoid Conjugate Vaccine in DRC (TyVECO). NCT05119426. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05119426. Accessed April 2, 2023."},{"issue":"7","key":"10.1016\/j.jvacx.2024.100568_b0290","doi-asserted-by":"crossref","first-page":"2150030","DOI":"10.1080\/21645515.2022.2150030","article-title":"Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV\u00ae) and measles or measles-mumps-rubella vaccines in 8\u20139 months-old Indian children","volume":"18","author":"Vadrevu","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jvacx.2024.100568_b0295","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijid.2020.10.103","article-title":"Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15\u201323 months in Burkina Faso","volume":"102","author":"Sirima","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100568_b0300","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijid.2021.05.061","article-title":"Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial","volume":"108","author":"Sirima","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"40","key":"10.1016\/j.jvacx.2024.100568_b0305","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1016\/j.vaccine.2022.08.034","article-title":"Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9\u201315 months old Nepalese infants","volume":"40","author":"Saluja","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100568_b0310","unstructured":"International Centre for Diarrhoeal Disease Research, Bangladesh. A Co-administration Study of Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR) Vaccines in Bangladesh. NCT05771779. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05771779?cond=Typhoid+Fever&draw=2&rank=60. Accessed April 1, 2023."},{"issue":"12 Suppl 2","key":"10.1016\/j.jvacx.2024.100568_b0315","doi-asserted-by":"crossref","first-page":"S781","DOI":"10.1093\/infdis\/jiab449","article-title":"Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas","volume":"224","author":"Birkhold","year":"2021","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100568_b0320","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-020-00302-9","article-title":"Vaccine Hesitancy as a Challenge or Vaccine Confidence as an Opportunity for Childhood Immunisation in India","volume":"9","author":"Agrawal","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100568_b0325","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4161\/hv.9313","article-title":"Vaccine desirability during an effectiveness trial of the typhoid fever polysaccharide Vi vaccine in Kolkata India","volume":"5","author":"Sur","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.jvacx.2024.100568_b0330","unstructured":"Hora R., Ray A., Dhawan V., Singh K., Mehra R., Kumari A., et al. Stakeholder perspectives on giving additional injectable vaccines in a single visit under universal immunisation program in India. The 13th International Conference on Typhoid & Other Invasive Salmonelloses; Kigali, Rwanda 2023."},{"key":"10.1016\/j.jvacx.2024.100568_b0335","unstructured":"Neuzil K. More typhoid conjugate vaccines, more impact, 2020. Available at: https:\/\/www.coalitionagainsttyphoid.org\/moretyphoidconjugatevaccines\/. Accessed February 26, 2023."},{"key":"10.1016\/j.jvacx.2024.100568_b0340","unstructured":"Gavi 2018. New typhoid vaccine to receive Gavi support. Available at: https:\/\/www.gavi.org\/news\/media-room\/new-typhoid-vaccine-receive-gavi-support. Accessed February 2, 2023."},{"issue":"7","key":"10.1016\/j.jvacx.2024.100568_b0345","doi-asserted-by":"crossref","first-page":"171","DOI":"10.15585\/mmwr.mm7207a2","article-title":"Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction - Worldwide, 2018\u20132022","volume":"72","author":"Hancuh","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jvacx.2024.100568_b0350","unstructured":"Gavi 2023. Amidst crises, Malawi showcases resilience with major vaccination push. Available at: https:\/\/www.gavi.org\/news\/media-room\/amidst-crises-malawi-showcases-resilience-major-vaccination-push. Accessed July 30, 2024."},{"issue":"12","key":"10.1016\/j.jvacx.2024.100568_b0355","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s13312-013-0292-9","article-title":"Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization","volume":"50","author":"Vashishtha","year":"2013","journal-title":"Indian Pediatr"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0360","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/ijph.IJPH_433_18","article-title":"Private sector vaccine share in overall immunization coverage in India: Evidence from private sector vaccine utilization data (2012\u20132015)","volume":"64","author":"Farooqui","year":"2020","journal-title":"Indian J Public Health"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0365","doi-asserted-by":"crossref","first-page":"e0001396","DOI":"10.1371\/journal.pgph.0001396","article-title":"Delivery cost of the first public sector introduction of typhoid conjugate vaccine in Navi Mumbai, India","volume":"3","author":"Song","year":"2023","journal-title":"PLOS Glob Public Health"},{"issue":"30","key":"10.1016\/j.jvacx.2024.100568_b0370","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1016\/j.vaccine.2021.06.003","article-title":"Cost effectiveness of typhoid vaccination in India","volume":"39","author":"Chauhan","year":"2021","journal-title":"Vaccine"},{"issue":"Supple 5","key":"10.1016\/j.jvacx.2024.100568_b0375","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/infdis\/jiab150","article-title":"Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study","volume":"224","author":"Ryckman","year":"2021","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100568_b0380","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2022.12.032","article-title":"Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness","volume":"41","author":"Burrows","year":"2023","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100568_b0385","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1473-3099(18)30804-1","article-title":"Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study","volume":"19","author":"Bilcke","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.jvacx.2024.100568_b0390","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.vaccine.2017.05.001","article-title":"Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings","volume":"35","author":"Antill\u00f3n","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100568_b0395","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1473-3099(21)00627-7","article-title":"Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study","volume":"22","author":"Birger","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jvacx.2024.100568_b0400","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/ofid\/ofad022","article-title":"Using Typhoid Conjugate Vaccines to Prevent Disease, Promote Health Equity, and Counter Drug-Resistant Typhoid Fever","volume":"10","author":"Nampota-Nkomba","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"39","key":"10.1016\/j.jvacx.2024.100568_b0405","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1016\/j.vaccine.2019.07.104","article-title":"Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementation","volume":"37","author":"Malik","year":"2019","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100568_b0410","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s13312-012-0151-0","article-title":"Introduction of Haemophilus influenzae type b (Hib) as pentavalent(DPT-HepB-Hib) vaccine in two states of India","volume":"49","author":"Gupta","year":"2012","journal-title":"Indian Pediatr"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0415","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/ijmm.IJMM_19_320","article-title":"Pneumococcal conjugate vaccine rollout in India: Expectations and challenges","volume":"37","author":"Varghese","year":"2019","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jvacx.2024.100568_b0420","unstructured":"John Snow India Private Limited (JSIPL) 2023. The Immunization Technical Support Unit (ITSU). Available at: https:\/\/jsiindia.in\/itsu.html. Accessed March 3, 2023."},{"key":"10.1016\/j.jvacx.2024.100568_b0425","unstructured":"Unicef 2022. Immunization coverage by antigen (country, regional, and global trends). Available at: https:\/\/data.unicef.org\/topic\/child-health\/immunization\/. Accessed March 3, 2023."},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1961471","article-title":"Cost of conducting Measles-Rubella vaccination campaign in India","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0435","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12960-021-00575-2","article-title":"Size, composition and distribution of health workforce in India: why, and where to invest?","volume":"19","author":"Karan","year":"2021","journal-title":"Hum Resour Health"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0440","doi-asserted-by":"crossref","first-page":"2009289","DOI":"10.1080\/21645515.2021.2009289","article-title":"Return on investment of the electronic vaccine intelligence network in India","volume":"18","author":"Gurnani","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100568_b0445","doi-asserted-by":"crossref","first-page":"e0241369","DOI":"10.1371\/journal.pone.0241369","article-title":"Programmatic assessment of electronic Vaccine Intelligence Network (eVIN)","volume":"15","author":"Gurnani","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100568_b0450","first-page":"39","article-title":"Adverse Event Following Immunization-prevention, monitoring and reporting in India","volume":"23","author":"Mogasale V.","year":"2021","journal-title":"Indian Journal of Practical Pediatrics"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0455","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12098-017-2532-9","article-title":"Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India","volume":"85","author":"Joshi","year":"2018","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.jvacx.2024.100568_b0460","unstructured":"Ministry of Health & Family Welfare, Government of India 2023. Integrated Disease Surveillance Project. National Centre for Disease Control, Directorate General of Health Services. Available at: https:\/\/idsp.mohfw.gov.in\/index.php. Accessed March 3, 2023."},{"key":"10.1016\/j.jvacx.2024.100568_b0465","unstructured":"Ministry of Health & Family Welfare, Government of India 2023. Integrated Health Information Platform. Available at: https:\/\/ihiplearning.in\/#!\/. Accessed March 3, 2023."},{"issue":"2","key":"10.1016\/j.jvacx.2024.100568_b0470","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/heapol\/czab114","article-title":"Public finance of universal routine childhood immunization in India: district-level cost estimates","volume":"37","author":"Schueller","year":"2022","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.jvacx.2024.100568_b0475","unstructured":"Gavi India 2023. Gavi support. Available at: https:\/\/www.gavi.org\/programmes-impact\/country-hub\/south-east-asia\/india. Accessed March 4, 2023."},{"issue":"11","key":"10.1016\/j.jvacx.2024.100568_b0480","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1093\/cid\/ciaa1429","article-title":"Can Existing Improvements of Water, Sanitation, and Hygiene (WASH) in Urban Slums Reduce the Burden of Typhoid Fever in These Settings?","volume":"72","author":"Im","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100568_bib481","article-title":"Research priorities to support typhoid conjugate vaccine decision-making in India: evidence assessment and stakeholder survey","volume":"0","author":"Mogasale","year":"2024","journal-title":"BMJ Public Health"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:08:26Z","timestamp":1786219706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":97,"alternative-id":["S2590136224001414"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100568","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Typhoid conjugate vaccine implementation in India: A review of supportive evidence","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100568"}}